Citius Pharmaceuticals, INC 8-K filings

Citius Pharmaceuticals has regained compliance with Nasdaq listing rules after its share price closed above $1.00 for 12 consecutive trading days.

Citius Pharmaceuticals will execute a 1-for-25 reverse stock split of its common stock, effective November 25, 2024, to increase its per share trading price and regain compliance with Nasdaq's minimum bid price requirement.

Citius Pharmaceuticals had a productive Type C meeting with the FDA regarding their Mino-Lok program, receiving clear guidance for a future New Drug Application submission.

Citius Pharmaceuticals has successfully completed a registered direct offering, raising $3 million through the sale of common stock and warrants.

Citius Pharmaceuticals has been granted an extension by Nasdaq to regain compliance with the minimum bid price rule by December 3, 2024, avoiding delisting.

Citius Pharmaceuticals and Citius Oncology reported encouraging preliminary results from a Phase I trial combining LYMPHIR and pembrolizumab, showing a 27% objective response rate and a 33% clinical benefit rate in patients with recurrent solid tumors.

Citius Pharmaceuticals has extended the employment agreement of its Executive Vice Chairman and the expiration dates of certain warrants.

Citius Pharmaceuticals has reached an agreement with Dr. Reddy's Laboratories for a partial deferral of a milestone payment related to the regulatory approval of LYMPHIR™.

Citius Pharmaceuticals received a delisting notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share and intends to appeal the decision.

Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a recommended treatment option for Cutaneous T-cell Lymphoma (CTCL).

Citius Pharmaceuticals has finalized the merger of its oncology subsidiary with TenX Keane Acquisition, creating Citius Oncology, Inc., which is set to begin trading on Nasdaq under the ticker CTOR.

Citius Pharmaceuticals reports FDA approval for LYMPHIR, completes the merger of its oncology subsidiary, and achieves key endpoints in a Phase 3 trial, while also detailing its financial results for the third quarter of 2024.

Citius Pharmaceuticals announced that the FDA has approved LYMPHIR for the treatment of relapsed or refractory cutaneous T-cell lymphoma, marking the company's first FDA-approved product.

Citius Pharmaceuticals announced its Mino-Lok antibiotic lock solution met its primary and secondary endpoints in a Phase 3 trial for treating catheter-related bloodstream infections.

Citius Pharmaceuticals announced its fiscal second quarter 2024 results, highlighted by the acceptance of the LYMPHIR biologics license application and progress in the Mino-Lok trial.

Citius Pharmaceuticals has successfully completed a registered direct offering, raising $15 million to support its clinical development programs and general corporate needs.

Citius Pharmaceuticals has extended the expiration date of warrants held by its CEO, EVP, and placement agents by one year to April 5, 2025.

The FDA has accepted Citius Pharmaceuticals' resubmitted Biologics License Application for LYMPHIR, a treatment for relapsed or refractory cutaneous T-cell lymphoma, with a target action date of August 13, 2024.

Citius Pharmaceuticals received an extension to regain compliance with Nasdaq's minimum bid price rule and held its 2024 annual meeting, electing board members and ratifying its accounting firm.

Citius Pharmaceuticals announced its fiscal first quarter 2024 results, highlighting progress in its clinical programs and a strategic merger to form a separate oncology-focused entity.

Citius Pharmaceuticals has resubmitted its Biologics License Application (BLA) to the FDA for LYMPHIR, a treatment for relapsed or refractory cutaneous T-cell lymphoma.

Citius Pharmaceuticals has nominated seasoned pharmaceutical executive Robert J. Smith to its Board of Directors, pending shareholder approval at the annual meeting in March.